dual glp 1 glucagon receptor agonists Discovery of Biased Dual-Agonists of Glucagon-Like Peptide and Receptors through Mutation of a Conserved Aspartate The current significance and prospects
Description
Recognizing the challenges posed by the limited availability of semaglutide and other GLP-1s, we've established robust partnerships with specialized compounding pharmacies

Jensen MD, Ryan DH, Apovian CM, et al

Compr Physiol
Lee S-Y, Wu S-T, Liang Y-J, et al

At 3 months, the exenatide group maintained a 5.6 cmCSF reduction relative to placebo (between-group difference: 4.1 mmHg, equivalent to 5.6 cmCSF), p = 0.058)

Front Endocrinol (Lausanne) 2019;10:260
